Literature DB >> 14607855

Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Dan Turner1, Bluma Brenner, Mark A Wainberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14607855      PMCID： PMC262455          DOI： 10.1128/cdli.10.6.979-981.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  34 in total

1.  Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.

Authors:  W Keulen; A van Wijk; R Schuurman; B Berkhout; C A Boucher
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

Authors:  J M Molina; G Chêne; F Ferchal; V Journot; I Pellegrin; M N Sombardier; C Rancinan; L Cotte; I Madelaine; T Debord; J M Decazes
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes.

Authors:  M Schmitt; E Harrer; A Goldwich; M Bäuerle; I Graedner; J R Kalden; T Harrer
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

5.  Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

Authors:  D Descamps; P Flandre; V Calvez; G Peytavin; V Meiffredy; G Collin; C Delaugerre; S Robert-Delmas; B Bazin; J P Aboulker; G Pialoux; F Raffi; F Brun-Vézinet
Journal:  JAMA       Date:  2000-01-12       Impact factor: 56.272

6.  Lamivudine resistance of HIV type 1 does not delay development of resistance to nonnucleoside HIV type 1-specific reverse transcriptase inhibitors as compared with wild-type HIV type 1.

Authors:  H Jonckheere; M Witvrouw; E De Clercq; J Anné
Journal:  AIDS Res Hum Retroviruses       Date:  1998-02-10       Impact factor: 2.205

7.  Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.

Authors:  M Tisdale; T Alnadaf; D Cousens
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

9.  The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  L F Rezende; W C Drosopoulos; V R Prasad
Journal:  Nucleic Acids Res       Date:  1998-06-15       Impact factor: 16.971

10.  Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.

Authors:  P Inouye; E Cherry; M Hsu; S Zolla-Pazner; M A Wainberg
Journal:  AIDS Res Hum Retroviruses       Date:  1998-06-10       Impact factor: 2.205
View more
  16 in total

1.  Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.

Authors:  Hong-Tao Xu; Maureen Oliveira; Peter K Quashie; Matthew McCallum; Yingshan Han; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Daniel Rajotte; Richard Bethell; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

3.  Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Authors:  Hong-Tao Xu; Eugene L Asahchop; Maureen Oliveira; Peter K Quashie; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Eugene L Asahchop; Maureen Oliveira; Matthew McCallum; Susan M Schader; Yingshan Han; Yudong Quan; Stefan G Sarafianos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

5.  Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.

Authors:  Selwyn J Hurwitz; Raymond F Schinazi
Journal:  Drug Discov Today Technol       Date:  2012

6.  Bayesian network analyses of resistance pathways against efavirenz and nevirapine.

Authors:  Koen Deforche; Ricardo J Camacho; Zehave Grossman; Marcelo A Soares; Kristel Van Laethem; David A Katzenstein; P Richard Harrigan; Rami Kantor; Robert Shafer; Anne-Mieke Vandamme
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

7.  The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Yingshan Han; Yudong Quan; Veronica Zanichelli; Mark A Wainberg
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

8.  High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs.

Authors:  Sydney J Bennett; Catherine Chunda-Liyoka; Lisa K Poppe; Katie Meinders; Chisanga Chileshe; John T West; Charles Wood
Journal:  AIDS       Date:  2020-10-01       Impact factor: 4.632

9.  Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency.

Authors:  Sophie M Bastarache; Thibault Mesplède; Daniel A Donahue; Richard D Sloan; Mark A Wainberg
Journal:  Viruses       Date:  2014-09-19       Impact factor: 5.048

10.  Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.

Authors:  Hanh T Pham; Thibault Mesplède; Mark A Wainberg
Journal:  Retrovirology       Date:  2016-04-30       Impact factor: 4.602
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.